These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12469692)

  • 1. Intranasal estradiol: new formulation. Intranasal oestrogen delivery system: just a gimmick.
    Prescrire Int; 2002 Dec; 11(62):163-5. PubMed ID: 12469692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
    Baksu B; Baksu A; Göker N; Citak S
    Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
    Genazzani AR; Cappagli B; Ciaponi M
    Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tibolone: new preparation. Menopausal symptoms: oestrogen-progestogen combinations are still the reference treatment.
    Prescrire Int; 2002 Jun; 11(59):79-82. PubMed ID: 12068842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen effects on neuroendocrine function: the new challenge of pulsed therapy.
    Genazzani AR; Bernardi F
    Climacteric; 2002 Jun; 5 Suppl 2():50-6. PubMed ID: 12482112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
    Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
    Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal versus transdermal matrix oestrogen replacement in Australasian women.
    Davis SR; Davison SL; Wilson S; Shepherd J; Lawton B
    Maturitas; 2005 Jun; 51(2):163-71. PubMed ID: 15917157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women.
    Castelo-Branco C; Coloma JL
    Gynecol Endocrinol; 2010 Jan; 26(1):23-9. PubMed ID: 19639494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of pulsed estrogen therapy: key factors for an improved compliance.
    Mattsson LA
    Climacteric; 2002 Jun; 5 Suppl 2():40-5. PubMed ID: 12482110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral administration of progestins for hormonal replacement therapy.
    Nath A; Sitruk-Ware R
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):88-96. PubMed ID: 19340703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss.
    Palacios S
    Climacteric; 2002 Jun; 5 Suppl 2():32-9. PubMed ID: 12482109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
    Hemelaar M; Kenemans P; Schalkwijk CG; Braat DD; van der Mooren MJ
    Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women.
    Naunton M; Al Hadithy AF; Brouwers JR; Archer DF
    Menopause; 2006; 13(3):517-27. PubMed ID: 16735950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
    Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
    Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do different delivery systems of estrogen therapy influence serum lipids differently in surgically menopausal women?
    Baksu B; Davas I; Agar E; Akyol A; Uluocak A
    J Obstet Gynaecol Res; 2007 Jun; 33(3):346-52. PubMed ID: 17578365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen.
    Rozenberg S; Pornel B; Koninckx PR; Palacios S; Christiansen C
    Hum Reprod; 2009 Jul; 24(7):1739-47. PubMed ID: 19351658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.